Label: SODIUM CITRATE AND CITRIC ACID- sodium citrate and citric acid monohydrate solution
- NDC Code(s): 84447-017-01, 84447-017-16
- Packager: Belleview Biosciences LLC
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: unapproved drug other
DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Drug Label Information
Updated April 8, 2025
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
DESCRIPTION
Sodium Citrate and Citric Acid Oral Solu on, USP is a stable and pleasant-tas ng systemic alkalizer containing sodium citrate and citric acid in a sugar-free
base. It is a non-par culate neutralizing buff er.
Sodium Citrate and Citric Acid Oral Solu on, USP contains in each teaspoonful (5 mL):
SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)
CITRIC ACID Monohydrate 334 mg (0.32 Molar)
Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).
INACTIVE INGREDIENTS: grape fl avoring, purifi ed water, sodium benzoate, sorbitol and sucralose. -
CLINICAL PHARMACOLOGY
Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.
-
INDICATIONS AND USAGE
Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.
Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.
- CONTRAINDICATIONS
-
PRECAUTIONS
Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.
-
ADVERSE REACTIONS
Sodium citrate and citric acid oral solution on is generally well tolerated, without any unpleasant side eff ects, when given in recommended doses to patients with normal renal function on and urinary output. However, as with any alkalinizing agent, caution on must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.
To report SUSPECTED ADVERSE REACTIONS, contact Kesin Pharma at 1-833-537-4679 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. - OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- For Systemic Alkalization
- As a neutralizing buffer
-
HOW SUPPLIED
Sodium Citrate and Citric Acid Oral Solu on, USP (colorless, grape fl avor) is supplied in the following oral dosage forms:
NDC 81033-017-15: 15 mL unit dose cup
NDC 81033-017-50: Case containing 100 unit-dose cups of 15 mL
NDC 81033-017-30: 30 mL unit dose cup
NDC 81033-017-51: Case containing 100 unit-dose cups of 30 mL - STORAGE:
- SPL UNCLASSIFIED SECTION
-
PRINCIPAL DISPLAY PANEL - Bulk Drum
NDC 84447-017-01
Sodium Citrate and Citric Acid Oral Solution USP
500 mg/334 mg per 5 mL
**Sugar, Alcohol, Gluten and Dye Free**
Each teaspoonful (5 mL) contains:
Sodium Citrate Dihydrate..........500 mg
Citric Acid Monohydrate............334 mg
Rx ONLY
Manufactured By:
Belleview Biosciences LLC
Brooksville, FL 34604
-
INGREDIENTS AND APPEARANCE
SODIUM CITRATE AND CITRIC ACID
sodium citrate and citric acid monohydrate solutionProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:84447-017 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SODIUM CITRATE (UNII: 1Q73Q2JULR) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) SODIUM CITRATE 500 mg in 5 mL ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID 334 mg in 5 mL Inactive Ingredients Ingredient Name Strength WATER (UNII: 059QF0KO0R) SORBITOL (UNII: 506T60A25R) SUCRALOSE (UNII: 96K6UQ3ZD4) SODIUM BENZOATE (UNII: OJ245FE5EU) Product Characteristics Color Score Shape Size Flavor GRAPE Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:84447-017-16 473 mL in 1 BOTTLE; Type 0: Not a Combination Product 04/08/2025 2 NDC:84447-017-01 200000 mL in 1 DRUM; Type 0: Not a Combination Product 04/08/2025 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 04/08/2025 Labeler - Belleview Biosciences LLC (131968803) Registrant - Belleview Biosciences LLC (131968803) Establishment Name Address ID/FEI Business Operations Belleview Biosciences LLC 131968803 manufacture(84447-017) , pack(84447-017) , label(84447-017)